Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Atea Pharmaceuticals, Inc.
  6. News
  7. Summary
    AVIR   US04683R1068

ATEA PHARMACEUTICALS, INC.

(AVIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about ATEA PHARMACEUTICALS, INC.
05/10TRANSCRIPT : Atea Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/10Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business..
AQ
05/03Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on Ma..
AQ
03/294794 : Characterization of the Toxicity Profile of AT-527 (Bemnifosbuvir), a Novel Guanosi..
PU
03/294793 : Lack of Reproductive and Developmental Toxicity for AT-527 (Bemnifosbuvir), an Oral..
PU
03/28Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Soci..
AQ
03/02JPMorgan Adjusts Price Target for Atea Pharmaceuticals to $8 From $10, Maintains Neutra..
MT
03/01SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $9 from $10, Keeps Market Per..
MT
02/28ATEA PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2021 Financial Results and Pro..
PU
02/28Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31..
CI
02/28TRANSCRIPT : Atea Pharmaceuticals, Inc., Q4 2021 Earnings Call, Feb 28, 2022
CI
02/28ATEA PHARMACEUTICALS : Fourth Quarter 2021 Financial Results Conference Call Presentation
PU
02/28Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended Decemb..
CI
02/28Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Pr..
AQ
More most relevant news
All news about ATEA PHARMACEUTICALS, INC.
05/10ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/10TRANSCRIPT : Atea Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/10Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business..
AQ
05/03Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on Ma..
AQ
03/294794 : Characterization of the Toxicity Profile of AT-527 (Bemnifosbuvir), a Novel Guanosi..
PU
03/294793 : Lack of Reproductive and Developmental Toxicity for AT-527 (Bemnifosbuvir), an Oral..
PU
03/28Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Soci..
AQ
03/02JPMorgan Adjusts Price Target for Atea Pharmaceuticals to $8 From $10, Maintains Neutra..
MT
03/01SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $9 from $10, Keeps Market Per..
MT
More news
News in other languages on ATEA PHARMACEUTICALS, INC.
05/10Atea Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 m..
02/28Atea Pharmaceuticals, Inc. publie ses résultats pour l'année complète se terminant le 3..
02/28Atea Pharmaceuticals, Inc. annonce ses résultats pour le quatrième trimestre clos le 31..
02/10Atea Pharmaceuticals, Inc. annonce des changements de direction
02/02Atea Pharmaceuticals, Inc. annonce la publication dans Nature Communications de données..
01/07Atea Pharmaceuticals, Inc. fait le point sur les priorités de développement clinique de..
2021Atea Pharmaceuticals va être ajouté à l'indice Nasdaq Biotech
2021ROCHE : feu vert européen pour le tocilizumab contre le Covid-19
2021Les actions du secteur de la santé affichent des gains modestes mercredi
2021Les actions du secteur de la santé en hausse modérée cet après-midi
More news
Analyst Recommendations on ATEA PHARMACEUTICALS, INC.
03/02JPMorgan Adjusts Price Target for Atea Pharmaceuticals to $8 From $10, Maintains Neutra..
MT
03/01SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $9 from $10, Keeps Market Per..
MT
02/16SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $10 from $11, Maintains Marke..
MT
02/01Morgan Stanley Adjusts Atea Pharmaceuticals Price Target to $6 From $7, Reiterates Unde..
MT
01/06Morgan Stanley Downgrades Atea Pharmaceuticals to Underweight From Equal Weight, Adjust..
MT
More recommendations
Press releases
05/10ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/10Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business..
AQ
05/03Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on Ma..
AQ
03/294794 : Characterization of the Toxicity Profile of AT-527 (Bemnifosbuvir), a Novel Guanosi..
PU
03/294793 : Lack of Reproductive and Developmental Toxicity for AT-527 (Bemnifosbuvir), an Oral..
PU
More press releases
Analysis
Atea plunges after COVID-19 treatment fails to help patients in study
Upcoming event on ATEA PHARMACEUTICALS, INC.
08/11/22Interim 2022 Earnings Release (Projected)
Upcoming sector events
07/27/22VERTEX PHARMACEUTICALS INCORPORATED : Interim 2022 Earnings Release (Projected)
07/27/22GILEAD SCIENCES, INC. : Interim 2022 Earnings Release (Projected)
08/04/22REGENERON PHARMACEUTICALS, INC. : Interim 2022 Earnings Release (Projected)
08/08/22BIONTECH SE : Interim 2022 Earnings Release
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs